Majić T

Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Psychiatry and Psychotherapy, Campus Charité Mitte, Berlin, Germany.

19 papers · 2 preprints · ORCID

ArticlePsilocybin

Long-Term Efficacy of Psilocybin with Adjunct Psychotherapy in Treatment-Resistant Major Depression: 6- and 12-Month Naturalistic Follow-Up of a Phase 2b Trial.

Mertens LJ, Betzler F, Brand M +24

Europe PMC2026
PreprintPsychedelics

Persisting Psychological Complications Following the Use of Classic Psychedelics: A Qualitative Study of Help-Seeking Experiences

Jöbstl LM, Lubahn B, Kaya E +7

Europe PMC2026
ArticlePsychedelics

Flashbacks, Hallucinogen Persisting Perception Disorder (HPPD), and Reactivations Following the Use of Classic Psychedelics: Classification and Therapeutic Management.

Žuljević MF, Majić T

Europe PMC2026
ArticlePsilocybin

Classifying Psychedelic-Related Complications.

Majić T, Gouzoulis-Mayfrank E, Evens R

Europe PMC2026
ArticlePsilocybin

Psychedelic-Related Psychosis: From Model Psychosis to Psychotherapy.

Bröcker AL, Majić T, Montag C

Europe PMC2026
ArticlePsychedelics

Managing Psychological Challenges in the Subacute ("Afterglow") Window of Psychedelic Drug Effects.

Evens R, Uyar A, Majić T

Europe PMC2026
ArticlePsilocybin

The Afterglow Inventory (AGI): Validation of a new instrument for measuring subacute effects of classic serotonergic psychedelics.

Majić T, Schmidt TT, Gröticke A +4

Europe PMC2025
ArticlePsilocybin

Sporadic use of classic psychedelics and neuropsychological performance: A cross-sectional analysis.

Reiche S, Hirschfeld T, Gröticke AL +11

Europe PMC2025
ArticlePsychedelics

On Minimizing Risk and Harm in the Use of Psychedelics.

Evans J, Aixalà M, Anderson BT +28

Europe PMC2025
ArticlePsilocybin

Neuropsychological profiles of patients suffering from hallucinogen persisting perception disorder (HPPD): A comparative analysis with psychedelic-using and non-using controls.

Leistenschneider G, Majić T, Reiche S +1

Europe PMC2024
ArticleMDMA

Cognitive functioning associated with acute and subacute effects of classic psychedelics and MDMA - a systematic review and meta-analysis.

Basedow LA, Majić T, Hafiz NJ +3

Europe PMC2024
ArticlePsilocybin

The psychedelic afterglow phenomenon: a systematic review of subacute effects of classic serotonergic psychedelics.

Evens R, Schmidt ME, Majić T +1

Europe PMC2023
ArticleLSD

Dose-response relationships of LSD-induced subjective experiences in humans.

Hirschfeld T, Prugger J, Majić T +1

Europe PMC2023
PreprintLSD

Dose-response relationships of LSD-induced subjective experiences in humans

Hirschfeld T, Prugger J, Prugger J +2

Europe PMC2022
ArticlePsilocybin

Methodological challenges in psychedelic drug trials: Efficacy and safety of psilocybin in treatment-resistant major depression (EPIsoDE) - Rationale and study design.

Mertens LJ, Koslowski M, Betzler F +9

Europe PMC2022
ArticlePsychedelics

Psychedelic Experiences During the Early COVID-19 Pandemic: Findings From an International Online Survey.

Evens R, Reiche S, Marek RM +9

Europe PMC2021
ArticlePsilocybin

Neuropsychological Functioning in Users of Serotonergic Psychedelics - A Systematic Review and Meta-Analysis.

Basedow LA, Riemer TG, Reiche S +2

Europe PMC2021
ArticleAyahuasca

Connected to the spirit of the frog: An Internet-based survey on Kambô, the secretion of the Amazonian Giant Maki Frog (<i>Phyllomedusa bicolor</i>): Motivations for use, settings and subjective experiences.

Majić T, Sauter M, Bermpohl F +1

Europe PMC2021
ArticlePsychedelics

Acute and subacute psychoactive effects of Kambô, the secretion of the Amazonian Giant Maki Frog (Phyllomedusa bicolor): retrospective reports.

Schmidt TT, Reiche S, Hage CLC +2

Europe PMC2020
ArticlePsilocybin

Serotonergic hallucinogens in the treatment of anxiety and depression in patients suffering from a life-threatening disease: A systematic review.

Reiche S, Hermle L, Gutwinski S +3

Europe PMC2018
ArticlePsilocybin

[Psychotherapy with Adjuvant use of Serotonergic Psychoactive Substances: Possibilities and Challenges].

Majić T, Jungaberle H, Jungaberle H +4

Europe PMC2017